Treatment of Primary Biliary Cholangitis with Features of Autoimmune Hepatitis

A subset of patients with primary biliary cholangitis present with concurrent features of autoimmune hepatitis — an overlap that requires a treatment approach targeting both components simultaneously.

Clinical Scenario

This protocol applies to patients with primary biliary cholangitis who show additional features of autoimmune hepatitis, defined by one or more of the following: severe or moderate interface hepatitis on liver histology, ALT greater than 5× the upper limit of normal, or IgG serum levels greater than 2× the upper limit of normal.

Background

Features of autoimmune hepatitis occur in approximately 10% of patients with PBC, either simultaneously at diagnosis or sequentially — sometimes years after the initial PBC diagnosis. Current guidelines recommend immunosuppressive treatment in patients with severe interface hepatitis, and consideration of such treatment in those with moderate interface hepatitis.

Treatment Approach (Summary)

Management addresses both the PBC and autoimmune hepatitis components. Oral UDCA at standard dosing is used for the PBC component, combined with immunosuppressive therapy. The full regimen — including the specific agents, combination strategy, and supporting evidence — is detailed in the structured protocol.

Complete regimen, sequencing, and clinical evidence available via the full protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/hep.32117

Patients with PBC may present with additional features of AIH in around 10% of cases, most often simultaneously, but sometimes sequentially even years after diagnosis of PBC.
EASL suggests immunosuppressive treatment in patients with severe interface hepatitis, and consideration in patients with moderate interface hepatitis.
The PBC component should be treated with UDCA at a standard dose.
Patients with PBC and typical features of AIH may benefit from immunosuppressive treatment in addition to UDCA.
Most patients have been treated with corticosteroids (mainly prednisolone/prednisone) and have shown overall response rates similar to patients with AIH.
When compared to patients with AIH, combined treatment with corticosteroids and azathioprine may result in less cumulative steroid-induced side effects.

View source ↗